Lead author of the INFINITY trial, William B. White, MD, answers our questions about the preliminary results of the trial and subsequent analyses the team plans to conduct.
Samantha Ellingson, PharmD, BCPS, and Timothy H. Self, PharmD—Series Editor
Samantha Ellingson, PharmD, BCPS, and...
When considering potential drug interactions with statin therapy, it is important to consider the hepatic pathways that could be negatively impacted with the addition of new medications.
William E. Boden, MD, discusses his research in which he and his colleagues tried to replicate the results seen in the REDUCE-IT trial. His research was also presented at ACC.19 Scientific Session.
Stephanie Chung, MBBS, from the National Institutes of Health, answers our questions about her research on a 1-hour glucose tolerance test for diagnosing diabetes in teenaged girls.
Deborah B. Horn, DO, MPH, from the University of Texas McGovern Medical School, talks about physical activity monitoring using fitness trackers, how to personalize each individual patient's...
In this commentary, Robert Rosenson, MD, explains that PCSK9 inhibitors may be a useful alternative therapy in lowering LDL cholesterol in individuals who are unable to tolerate statins at the doses...
Consultant360 spoke with Dr James L Januzzi Jr, who recently co-authored the “2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart...
In part 4 of our series on lipid management, Paul Jellinger, MD, explains the answer to the quiz question from part 3 of the series and talks about the role of the MESA Study in the treatment of...
